Previous 10 | Next 10 |
Summary Charles River Laboratories' fourth quarter of 2022 was its strongest quarter in the company’s history. However, the company’s stock dropped ~12% because of challenges the company is facing with non-human primate supply resulting in 2023 guidance coming in below est...
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Charles River To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - February 23, 2023) - Faruqi & Faruqi, LLP, a leading national securities law fi...
After a more than 10% decline in the previous session, Charles River Laboratories ( NYSE: CRL ) gained ~2% Thursday as Guggenheim upgraded the non-clinical contract research organization (CRO) despite its underwhelming outlook. Charles River ( CRL ) reported better-than-expect...
Charles River Laboratories International, Inc. (CRL) Q4 2022 Earnings Conference Call February 22, 2023 8:30 AM ET Company Participants Todd Spencer – Vice President-Investor Relations Jim Foster – Chairman, President and Chief Executive Officer Flavia Pe...
Despite announcing better-than-expected financials for Q4 2022, Charles River Laboratories ( NYSE: CRL ) lost ~10% pre-market Wednesday after the non-clinical contract research organization issued an underwhelming outlook amid supply constraints. In November, the U.S. Department o...
The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Charles River Laboratories International, Inc. 2022 Q4 - Results - Earnings Call Presentation
Charles River Laboratories press release ( NYSE: CRL ): Q4 Non-GAAP EPS of $2.98 beats by $0.23 . Revenue of $1.1B (+21.5% Y/Y) beats by $60M . 2023 GUIDANCE: Revenue growth, reported of 1.5% – 4.5% vs. estimated growth of 6.08% Y/Y; Non-GAAP EPS estimate of...
– Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48 and Non-GAAP Earnings per...
Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagshi...
Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseases Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics , a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announc...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Charles River Laboratories International Inc. Website:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...